Cristescu et al. showed for different cancer types, including HNSCC, that TMB, PD-L1 expression, and T-cell inflamed gene expression profiles measure different aspects of the tumor immune response, as they are independent markers to predict the efficacy of anti-PD-1/PD-L1 therapy [113]. This evidence concerns the gene CD274 and neoplasm.